Opportunities and challenges in drug discovery targeting metabotropic glutamate receptor 4

Expert Opinion on Drug Discovery
Claudia VolpiUrsula Grohmann

Abstract

Until recently, metabotropic glutamate receptor 4 (mGlu4) has not received adequate attention in terms of drug targeting when compared to other members of the same mGlu receptor family, possibly because of the difficulties encountered in developing highly selective, either orthosteric or allosteric, ligands for this receptor. Areas covered: This review gives to discussion to the past and recent advances (between 2012-2017) in targeting the mGlu4 receptor for the treatment of disorders of the central nervous system (CNS) as well as immunological (neuroinflammation) and metabolic diseases (diabetes). Chemical structures, properties, and pharmacological properties discussed herein were retrieved from the scientific literature databases, PubMed and Google Scholar. Expert opinion: The fertile field of mGlu receptor positive allosteric modulators (PAMs) has recently led to the discovery of foliglurax, a highly selective mGlu4 receptor PAM with optimal bioavailability after oral administration and excellent brain distribution. However, further elucidation of the biological properties of the mGlu4 receptor, including expression and its signalling profile in distinct tissues and cells are still awaited in order to establish the mGlu4 re...Continue Reading

References

Jan 1, 1992·Neuron·Y TanabeS Nakanishi
Jan 6, 1994·Nature·B R Conklin, H R Bourne
Jan 1, 1997·Annual Review of Pharmacology and Toxicology·P J Conn, J P Pin
Aug 1, 1997·General Pharmacology·C Thomsen
Apr 1, 1998·Nature·J Banchereau, R M Steinman
Jul 4, 1998·Brain Research. Brain Research Reviews·S NakanishiM Okada
Feb 12, 1999·Brain Research. Brain Research Reviews·R Anwyl
Oct 26, 1999·Neuropharmacology·D D SchoeppJ A Monn
Nov 24, 1999·The Journal of Biological Chemistry·D R HampsonH Thøgersen
May 10, 2003·Trends in Immunology·Ursula GrohmannPaolo Puccetti
Jun 5, 2003·Pharmacology & Therapeutics·Jean-Philippe PinLaurent Prézeau
Nov 1, 2003·Proceedings of the National Academy of Sciences of the United States of America·Michael J MarinoP Jeffrey Conn
Dec 23, 2003·European Journal of Biochemistry·Eiichi HinoiYukio Yoneda
Oct 20, 2004·The Journal of Experimental Medicine·Francesca FallarinoPaolo Puccetti
Feb 3, 2005·Gastroenterology·Amanda J PageL Ashley Blackshaw
Apr 5, 2005·The Journal of Pharmacology and Experimental Therapeutics·Stuart MaudsleyLouis M Luttrell
May 4, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hee Jin ChangJae-Gahb Park
Nov 8, 2005·Journal of Neurochemistry·Alexander A BoldyrevPeter Johnson
Apr 21, 2006·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Qian JiangJian Feng
Aug 11, 2006·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Luisa IacovelliFerdinando Nicoletti
Oct 24, 2006·Current Opinion in Pharmacology·Urs GerberPascal Benquet
Dec 26, 2006·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·Ralf Enz
Mar 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Takanori MutoHisato Jingami
Sep 4, 2007·Nature Reviews. Immunology·Paolo Puccetti, Ursula Grohmann
Nov 8, 2007·Nature Reviews. Neuroscience·Anastassios V Tzingounis, Jacques I Wadiche
Mar 29, 2008·Neuropharmacology·Richard L YoungL Ashley Blackshaw
Jul 26, 2008·ACS Chemical Biology·Thomas M Bridges, Craig W Lindsley
Dec 23, 2008·Bioorganic & Medicinal Chemistry Letters·Richard WilliamsCraig W Lindsley

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here